May 21, 2024

Biosimilar Monoclonal Antibody Market Size To Grow USD 69 Billion by 2032

The global biosimilar monoclonal antibody market size was estimated to be around US$ 8.6 billion in 2022. It is projected to reach US$ 69 billion by 2032, indicating a CAGR of 23.2% from 2023 to 2032.

Biosimilar Monoclonal Antibody Market Size 2023 To 2032

Key Points:

  • In 2022, North America accounted for over 35% of the total revenue.
  • The Asia-Pacific region is expected to experience the highest Compound Annual Growth Rate (CAGR) of 8.3% between 2023 and 2032.
  • Within the “Type” category, the infliximab segment dominated the market with a 32% share in 2022.
  • The adalimumab segment is projected to exhibit significant growth, with an anticipated CAGR of 24.7% from 2023 to 2032.
  • In terms of “Indication,” the oncology segment secured a revenue share exceeding 44% in 2022.
  • The autoimmune diseases segment is forecasted to register the fastest CAGR throughout the projected period.
  • Among “End-users,” the hospital segment led the market in 2022, holding a substantial 49% market share.
  • The “others” segment is expected to witness the fastest CAGR during the projected period.

Overview:

The Biosimilar Monoclonal Antibody Market refers to the competitive landscape and economic dynamics surrounding the production and distribution of biosimilar versions of monoclonal antibodies. Monoclonal antibodies are laboratory-produced molecules designed to mimic the immune system’s ability to fight off harmful pathogens. In the context of biosimilars, these are highly similar versions of existing monoclonal antibodies whose patents have expired.

Drivers:

This market is driven by the increasing demand for cost-effective alternatives to biologic drugs, as biosimilar monoclonal antibodies have the potential to offer comparable therapeutic effects at a lower cost. The overview of the Biosimilar Monoclonal Antibody Market typically includes insights into regulatory frameworks, research and development activities, market trends, and the competitive landscape among pharmaceutical companies

The market research report on the Biosimilar monoclonal antibody market provides a comprehensive analysis of various key aspects. It includes the definition, classification, and application of Biosimilar monoclonal antibody products. The report examines the development trends, competitive landscape, and industrial chain structure within the industry. Furthermore, it presents an overview of the industry, analyzes national policies and planning, and offers insights into the latest market dynamics and opportunities at a global level.

Get a Sample: https://www.precedenceresearch.com/sample/3400

Biosimilar Monoclonal Antibody Market Scope

Report Coverage Details
Growth Rate from 2023 to 2032 CAGR of 23.2%
Market Size in 2023 USD 10.55 Billion
Market Size by 2032 USD 69 Billion
Largest Market North America
Base Year 2022
Forecast Period 2023 to 2032
Segments Covered By Type, By Indication, and By End User
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Read More: Risk Analytics Market Size to Garner USD 79.24 Billion by 2032

The report presents the volume and value-based market size for the base year 2022 and forecasts the market’s growth between 2023 and 2032. It estimates market numbers based on product form and application, providing size and forecast for each application segment in both global and regional markets.

Focusing on the global Biosimilar monoclonal antibody market, the report highlights its status, future forecasts, growth opportunities, key market players, and key market regions such as the United States, Europe, and China. The study aims to present the development of the Biosimilar monoclonal antibody market by considering factors like Year-on-Year (Y-o-Y) growth, in addition to Compound Annual Growth Rate (CAGR). This approach enables a better understanding of market certainty and the identification of lucrative opportunities.

Regarding production, the report investigates the capacity, production, value, ex-factory price, growth rate, and market share of major manufacturers, regions, and product types. On the consumption side, the report focuses on the regional consumption of Biosimilar monoclonal antibody products across different countries and applications.

Buyers of the report gain access to verified market figures, including global market size in terms of revenue and volume. The report provides reliable estimations and calculations for global revenue and volume by product type from 2023 to 2032. It also includes accurate figures for production capacity and production by region during the same period.

The research includes product parameters, production processes, cost structures, and data classified by region, technology, and application. Furthermore, it conducts SWOT analysis and investment feasibility studies for new projects.

This in-depth research report offers valuable insights into the Biosimilar monoclonal antibody market. It employs an objective and fair approach to analyze industry trends, supporting customer competition analysis, development planning, and investment decision-making. The project received support and assistance from technicians and marketing personnel across various links in the industry chain.

The competitive landscape section of the report provides detailed information on Biosimilar monoclonal antibody market competitors. It includes company overviews, financials, revenue generation, market potential, research and development investments, new market initiatives, global presence, production sites, production capacities, strengths and weaknesses, product launches, product range, and application dominance. However, the data points provided only focus on the companies’ activities related to the Biosimilar monoclonal antibody market.

Prominent players in the market are expected to face tough competition from new entrants. Key players are targeting acquisitions of startup companies to maintain their dominance. The report

Reasons to Purchase this Report:

  • Comprehensive market segmentation analysis incorporating qualitative and quantitative research, considering the impact of economic and policy factors.
  • In-depth regional and country-level analysis, examining the demand and supply dynamics that influence market growth.
  • Market size in USD million and volume in million units provided for each segment and sub-segment.
  • Detailed competitive landscape, including market share of major players, recent projects, and strategies implemented over the past five years.
  • Comprehensive company profiles encompassing product offerings, key financial information, recent developments, SWOT analysis, and employed strategies by major market players.

Biosimilar Monoclonal Antibody Market Players

  • Roche
  • Novartis
  • Pfizer
  • Samsung Bioepis
  • Amgen
  • Mylan
  • Teva Pharmaceutical Industries
  • Biogen
  • Celltrion
  • Fresenius Kabi
  • Sandoz
  • Boehringer Ingelheim
  • Merck
  • Amneal Pharmaceuticals
  • Biocon

Market Segmentations

By Type

  • Adalimumab
  • Bevacizumab
  • Infliximab
  • Rituximab
  • Trastuzumab
  • Others

By Indication

  • Oncology
  • Autoimmune diseases
  • Others

By End User

  • Hospitals
  • Cancer treatment centers
  • Others

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Biosimilar Monoclonal Antibody Market 

5.1. COVID-19 Landscape: Biosimilar Monoclonal Antibody Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Biosimilar Monoclonal Antibody Market, By Type

8.1. Biosimilar Monoclonal Antibody Market Revenue and Volume, by Type, 2023-2032

8.1.1 Adalimumab

8.1.1.1. Market Revenue and Volume Forecast (2020-2032)

8.1.2. Bevacizumab

8.1.2.1. Market Revenue and Volume Forecast (2020-2032)

8.1.3. Infliximab

8.1.3.1. Market Revenue and Volume Forecast (2020-2032)

8.1.4. Rituximab

8.1.4.1. Market Revenue and Volume Forecast (2020-2032)

8.1.5. Trastuzumab

8.1.5.1. Market Revenue and Volume Forecast (2020-2032)

8.1.6. Others

8.1.6.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 9. Global Biosimilar Monoclonal Antibody Market, By Indication

9.1. Biosimilar Monoclonal Antibody Market Revenue and Volume, by Indication, 2023-2032

9.1.1. Oncology

9.1.1.1. Market Revenue and Volume Forecast (2020-2032)

9.1.2. Autoimmune diseases

9.1.2.1. Market Revenue and Volume Forecast (2020-2032)

9.1.3. Others

9.1.3.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 10. Global Biosimilar Monoclonal Antibody Market, By End User 

10.1. Biosimilar Monoclonal Antibody Market Revenue and Volume, by End User, 2023-2032

10.1.1. Hospitals

10.1.1.1. Market Revenue and Volume Forecast (2020-2032)

10.1.2. Cancer treatment centers

10.1.2.1. Market Revenue and Volume Forecast (2020-2032)

10.1.3. Others

10.1.3.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 11. Global Biosimilar Monoclonal Antibody Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.1.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.1.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.1.4. U.S.

11.1.4.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.1.4.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.1.4.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.1.5.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.1.5.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.2. Europe

11.2.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.2.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.2.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.2.4. UK

11.2.4.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.2.4.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.2.4.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.2.5. Germany

11.2.5.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.2.5.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.2.5.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.2.6. France

11.2.6.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.2.6.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.2.6.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.2.7.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.2.7.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.3. APAC

11.3.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.3.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.3.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.3.4. India

11.3.4.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.3.4.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.3.4.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.3.5. China

11.3.5.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.3.5.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.3.5.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.3.6. Japan

11.3.6.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.3.6.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.3.6.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.3.7.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.3.7.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.4. MEA

11.4.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.4.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.4.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.4.4. GCC

11.4.4.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.4.4.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.4.4.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.4.5. North Africa

11.4.5.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.4.5.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.4.5.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.4.6. South Africa

11.4.6.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.4.6.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.4.6.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.4.7.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.4.7.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.5. Latin America

11.5.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.5.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.5.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.5.4. Brazil

11.5.4.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.5.4.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.5.4.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.5.5.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.5.5.3. Market Revenue and Volume Forecast, by End User (2020-2032)

Chapter 12. Company Profiles

12.1. Roche

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Novartis

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Pfizer

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Samsung Bioepis

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Amgen

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Mylan

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Teva Pharmaceutical Industries

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Biogen

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Celltrion

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Fresenius Kabi

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.pharma-geek.com

Prathamesh

I have completed my education in Bachelors in Computer Application. A focused learner having a keen interest in the field of digital marketing, SEO, SMM, and Google Analytics enthusiastic to learn new things along with building leadership skills.

View all posts by Prathamesh →

Leave a Reply

Your email address will not be published. Required fields are marked *